rvsv∆g-lasv-gpc
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 23, 2021 (NCT04794218)
Timeline
Indications
Studied for
Mechanism of action
- Lassa virusImmunity, active
Lassa virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05868733 | Phase 2 | Jul 31, 2023 | Coalition for Epidemic Preparedness Innovations, International AIDS Vaccine Initiative |
| NCT04794218 | Phase 1 | Jun 23, 2021 | East West Medical Research Institute, George Washington University, Harvard University, International AIDS Vaccine Initiative, Redemption Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| International AIDS Vaccine Initiative | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2023 |
| East West Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| George Washington University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Redemption Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1